BioNTech Snaps Up Pancreatic Cancer Antibody, US Infrastructure

 
• By John Davis

Europe’s largest private family-backed biotech adds to its antibody pipeline and its infrastructure in the US with assets from MabVax Therapeutics, in order to pioneer patient-specific immunotherapies for cancer and infections.  

Pancreas
Pancreatic cancer is crying out for new approaches to therapy. • Source: Shutterstock

More from Deals

More from Business